

Characterization of *Erysipelothrix rhusiopathiae* strains isolated from acute swine erysipelas outbreaks in Eastern China

Yao ZOU¹⁾, Xiaoming ZHU¹⁾, Hassan Mushtaq MUHAMMAD²⁾, Ping JIANG¹⁾ and Yufeng LI^{1)*}

¹⁾Key Laboratory of Bacteriology, Ministry of Agriculture, College of Veterinary Medicine, Nanjing Agricultural University, Nanjing 210095, China

²⁾Department of Epidemiology and Public Health, Faculty of Veterinary Science, University of Veterinary and Animal Sciences, Lahore, Pakistan

(Received 8 November 2014/Accepted 21 January 2015/Published online in J-STAGE 3 February 2015)

ABSTRACT. Recently, a series of acute swine erysipelas outbreaks occurred in Eastern China. Eight strains isolated from cases of septicemia were determined as serotype 1a, and 4 of the isolates were resistant to acriflavine. One isolate strain named HX130709 was attenuated on agar media containing acriflavine dye. The 432-bp hypervariable region in *spaA* gene of the field and attenuated strains were amplified and sequenced. It was further compared with the vaccine strain G₄T₁₀, and thus, the eight field strains can be divided into four *spaA*-types. The partial *spaA* gene analysis also showed that no point mutations occurred among different archived passages of HX130709 during the attenuation. Results of pulsed-field gel electrophoresis showed that eight distinct patterns with 22 to 30 DNA fragment bands were produced from field strains, and twelve distinct patterns with 23 to 27 DNA fragment bands were produced from different passages of the attenuated strains. Mouse pathogenicity test showed that the mortality of the mice infected with 10⁴ CFU field strains was 100% and the attenuation of strain HX130709 occurred between 46 and 50 passages. All the field and attenuated strains were highly sensitive to β-lactam antibiotics, tetracyclines and macrolides. So, we can make conclusions that the acute swine erysipelas outbreaks in Eastern China were caused by serotype 1a *E. rhusiopathiae* strains with different biochemical characteristics, and the virulence of serotype 1a *E. rhusiopathiae* strains is unrelated with some point mutations in 432-bp hypervariable region of the *spaA* gene.

KEY WORDS: acriflavine, attenuation, *Erysipelothrix rhusiopathiae*, PFGE, *spa*

doi: 10.1292/jvms.14-0589; *J. Vet. Med. Sci.* 77(6): 653–660, 2015

Erysipelothrix rhusiopathiae (*E. rhusiopathiae*) is a small gram-positive, slender and straight or slightly rod bacterium that causes erysipelas in swine and a wide spectrum of diseases in other animals, like sheep, some fishes, reptiles and birds. *E. rhusiopathiae* is also an important pathogen with respect to erysipeloid, a skin disease in humans [22]. This bacterium has been isolated in most parts of the world, from sick and healthy animals (pork, seafood and chicken) and even from the environment they lived [1, 3]. Among the 15 serotypes of *E. rhusiopathiae*, serotypes 1a, 1b and 2 are the most important agents affecting swine industry [2, 5, 8, 14, 17, 22].

Due to the importance of swine erysipelas, vaccines with killed organisms and attenuated live vaccines were developed. In 1932, an acriflavine-resistant attenuated live vaccine was developed in Japan. This vaccine strain Koganei 65-0.15 (serotype 1a) was attenuated by 65 passages on agar media containing 0.15% of an acriflavine dye [15]. Though outbreaks of acute septicemia or subacute urticaria of erysipelas have decreased dramatically by using the live vaccine, a

chronic form of erysipelas found during meat inspections in slaughterhouses has been increasing [11]. After 1985, about 2,000 pigs annually have been shown to have either acute or sub-acute infections [19]. In the United States, erysipelas cases were recorded with increasing frequency in both vaccinated and non-vaccinated pigs during the summer of 2001 [13]. Since swine erysipelas reappeared as a clinical problem in pig populations in Japan and the Midwestern United States, it has been considered as a reemerging disease that contributes substantially to economic losses in the swine industry [1, 2, 8].

It has been demonstrated that pulsed-field gel electrophoresis (PFGE) can be used to differentiate *E. rhusiopathiae* strains [12, 13]. Recent studies have focused on characterization of strains based on their *spa* type, whose gene encodes a surface protective antigen (Spa) [7, 9, 16]. The Spa proteins of *E. rhusiopathiae* can be classified into 3 molecular species, named SpaA (produced by serovars 1a, 1b, 2, 5, 8, 9, 12, 15, 16, 17 and N), SpaB (produced by serovars 4, 6, 11, 19 and 21) and SpaC (produced by serovar 18) [18]. More recently, a method for discrimination between a Japanese vaccine strain and the field strains was developed based on the nucleotide sequencing of a 432-bp hypervariable region in the *spaA* gene [11].

In 2009, sporadic outbreaks of acute swine erysipelas occurred, and one strain of *E. rhusiopathiae* was isolated from Siyang county of Jiangsu province. However, a wave of acute swine erysipelas outbreaks was seen in Eastern China, and seven other *E. rhusiopathiae* strains were isolated since

*CORRESPONDENCE TO: LI, Y., Key Laboratory of Bacteriology, Ministry of Agriculture, College of Veterinary Medicine, Nanjing Agricultural University, Nanjing 210095, China.
e-mail: yufengli@njau.edu.cn

©2015 The Japanese Society of Veterinary Science

This is an open-access article distributed under the terms of the Creative Commons Attribution Non-Commercial No Derivatives (by-nc-nd) License <<http://creativecommons.org/licenses/by-nc-nd/3.0/>>.

the summer of 2013. In the present study, the *spaA* sequence analysis in combination with serotyping, PFGE, acriflavine resistance, mouse pathogenicity and antimicrobial susceptibility tests were used to identify and characterize recent field strains of *E. rhusiopathiae* from acute swine erysipelas. Then, one strain HX130709 was attenuated by 55 passages on agar media containing a gradually increasing concentration (0.0025% to 0.03%) of acriflavine dye and sequenced every five passages to see if any mutations occurred in the hypervariable region of *spaA* gene during the attenuation.

MATERIALS AND METHODS

Bacteria isolation: BHI-T 80 agar: BHI-T 80 agar and broth were used for isolation of *E. rhusiopathiae* strains from tissue samples. The strains were identified and confirmed as *E. rhusiopathiae* by polymerase chain reaction (PCR) [18] after Gram stain and microscopic examination. All strains were isolated from cases of acute swine erysipelas causing sudden death of fattening pigs and postpartum sows in 2009 (1 strain) and 2013 (7 strains) and were named after the isolation districts and time (Table 1).

G₄T₁₀ strain (serotype 1a), a widely used commercial vaccine in China, was used as a reference attenuated strain with acriflavine resistance.

Serotyping: Serotyping was done on all the 8 field *E. rhusiopathiae* strains as described previously with some modifications [21]. All the culture supernatants were prepared following the schedule provided by Dr. Tanja Opriessnig (Veterinary Diagnostic Laboratory, College of Veterinary Medicine, Iowa State University, Ames, Iowa, U.S.A.). In brief, a pure culture was grown at 37°C for 48 hr in 30 ml of BHI broth (Binhe Microorganism Reagent, Hangzhou, China) supplemented with 10% bovine serum (Tianhang Biological Technology, Deqing, China). The culture was treated with formalin solution (final concentration of 1%) (Xilong chemical corporation, Shantou, China), held at room temperature for 24 hr, harvested by centrifugation and washed three times in 1 × PBS buffer containing 5% formalin. Washed cells were suspended in 1 ml of distilled water and autoclaved at 121°C for 45 min. The supernatant was collected and delivered to Dr. Tanja Opriessnig's lab for the agar gel precipitation test. Reactions were recorded after 24 hr.

Analysis of the 432-bp hypervariable region in the *spaA* gene of different strains: Primers Erko-1F (5'-GT-GAAACACCGTATTTAGTA-3') and Erko-2R (5'-TTCAAGAAGTTCCTGTAGTTT-3') were used to amplify the highly variable region of the *spaA* gene [11]. Briefly, genomic DNA of *E. rhusiopathiae* strains was prepared using bacterial DNA Kit (OMEGA, Norcross, GA, U.S.A.). Polymerase chain reaction (PCR) was performed as described elsewhere [18] under the following conditions with some modifications: PrimeSTAR HS DNA Polymerase (*TaKaRa*, Tokyo, Japan) was used to perform PCR; a denaturation step at 94°C for 3 min followed by 35 cycles of denaturation at 94°C for 45 sec; annealing at 55°C for 30 sec and extension at 72°C for 30 sec; and final extension of 5 min. For each

strain, PCR was performed three times, and each time, the PCR products were ligated with the pMD19-T Simple Vector (*TaKaRa*), and then, three colonies of each ligation product were sent to Invitrogen (Life Technologies, Shanghai, China) for sequencing. The DNA sequences were analyzed as described previously [11].

Pulsed-field gel electrophoresis: Chromosomal DNAs from the strains were digested with *Sma*I, and PFGE was performed 3 times according to Opriessnig *et al.* [13]. Electrophoresis was carried out for 23 hr at 14°C and 6 V with pulse times from an initial 1.2 sec to a final 30 sec. PFGE patterns were detected by UV transillumination after staining by SYBR Gold nucleic acid gel stain (S11494, Life technologies). A lambda ladder PFG marker (N0340s, NEB, Ipswich, MA, U.S.A.) was used as DNA size standard.

Acriflavine resistance test: The acriflavine resistance of all the eight strains was examined by streaking strains onto agar plates containing 0.04, 0.03, 0.02, 0.015, 0.01, 0.075, 0.005, 0.0025, 0.00125 or 0% acriflavine (Aladdin, Shanghai, China). The acriflavine agar plates were prepared by adding 1% acriflavine (dissolved in distilled water) to the sterilized basal medium (BHI-T 80 agar). The isolates were cultivated in 3 ml BHI-T 80 broth overnight at 37°C and were then streaked onto the agar plates. The vaccine strain (G₄T₁₀) was also streaked onto each plate as a positive control. The growth on the plates was observed after incubation at 37°C for 48 hr. Acriflavine resistance was determined by the highest concentration at which a strain showed almost the same growth as on the agar that did not contain acriflavine [8, 9, 11].

Attenuation of strain HX130709: Strain HX130709a (derived from strain HX130709) was attenuated by 55 passages on BHI-T 80 agar containing a gradually increasing concentration (0.0025% to 0.03%) of acriflavine dye. Bacteria were collected and stored under -70°C every five passages during the attenuation. Finally, the 432-bp partial *spaA* genes of all the archived strains were amplified for sequence analysis, and the virulence of each archived strain was confirmed in mice.

Mouse pathogenicity tests: One hundred and sixty-five female ICR mice of six-week-age were purchased from the Laboratory Animal Centre of Nantong University (Nantong, China). The animals were cared for in accordance with the *Guide for the Care and Use of Laboratory Animals* (1996, published by National Academy Press, NW, Washington, DC, U.S.A.). The animal experiments were approved by the Institutional Animal Care and Ethics Committee of Nanjing Agricultural University (Approval No. IACEC-NAU-20100902).

A total of 90 female ICR mice of six-week-age were given subcutaneous injections in the right groin with 10⁴ colony forming units (CFU)/ 0.1 ml of the isolates or the vaccine strain. A group of 10 mice served as an untreated control. Since a positive correlation between the isolate's CFU and OD value had been built in advance (data not shown), the number of bacteria injected into each mouse was almost the same. Mice were observed every 12 hr to detect clinical signs of the disease for the subsequent 14 days [8].

Table 1. Strains used in the study and eight field strains isolated from cases of septicemia causing acute death of fattening pigs and postpartum sows in Eastern China

Strains	Date Isolated	Area Isolated	GenBank Accession number	Serotype	Country of Isolation
Serotype 1a (Fujisawa)	unknown	unknown	AB259652.1	1a	Japan
G ₄ T ₁₀	unknown	unknown	KJ645072	1a	unknown
SY091027	27/10/2009	Siyang	KJ645080	1a	China
NZ130701	01/07/2013	Nanzhang	KJ645073	1a	China
HX130709	09/07/2013	Hexian	KJ645074	1a	China
XC130710	10/07/2013	Xuancheng	KJ645075	1a	China
SH130723	23/07/2013	Sihong	KJ645076	1a	China
YC130820 ^{a)}	20/08/2013	Yancheng	KJ645077	1a	China
YC130828 ^{a)}	28/08/2013	Yancheng	KJ645078	1a	China
YC131115 ^{a)}	15/11/2013	Yancheng	KJ645079	1a	China

a) Isolates YC130820, YC130828 and YC131115 were originated from three different farms in Yancheng.

Another 60 female ICR mice of six-week-age were given subcutaneous injections in the right groin with 10⁴ CFU/ 0.1 ml of the isolate strain HX130709 (F0) and different passages of the attenuated strain HX130709a (F5, F10, F15, F20, F25, F30, F35, F40, F45, F50 and F55). A group of 5 mice served as an untreated control. Mice were observed as above.

Antimicrobial susceptibility test: Each isolate was cultured in 3 ml BHI-T 80 broth overnight at 37°C. Then, 0.1 ml of the bacterial culture of each isolate was dropped onto BHI-T 80 agar, after which, antibiotic susceptibility discs (Binhe Microorganism Reagent) were put onto the BHI-T 80 agar. The diameter of the bacteriostatic circle was measured after incubation at 37°C for 24 hr. The susceptibility was determined according to instructions of the Clinical and Laboratory Standards Institute (CLSI) [4].

RESULTS

Serotyping and acriflavine resistance: All the eight *E. rhusiopathiae* isolates were determined to be serotype 1a (Fig. 1), which was finished by the laboratory of Dr. Tanja Opriessnig (Veterinary Diagnostic Laboratory, College of Veterinary Medicine, Iowa State University). The results of the acriflavine resistant test are shown in Table 2. Out of the total 8 isolates, 3 (37.5%) showed culture growth on the BHI-T 80 agar containing 0.02% acriflavine, which was identical to the growth of G₄T₁₀ strain (positive control).

Sequence analysis of the 432-bp hypervariable region in the *spaA* gene: According to Nagai *et al.* [11], different nucleotide substitutions in the 432-bp hypervariable region on the *spaA* gene of the eight *E. rhusiopathiae* field strains and the Japanese official challenge strain Fujisawa comparing with the vaccine strain G₄T₁₀ are shown in Table 3. According to the different substitutions, *spaA* can be divided into




Fig. 1. Genetic relationship between 8 *E. rhusiopathiae* field isolates and 1 vaccine strain and schematic representation of 8 different PFGE patterns obtained after restriction digestion with *Sma* I. The classification and divergence of isolates were calculated by the unweighted pair group method with averages from the PFGE results. At 5% divergence, 3 PFGE groups (A-C) were present; group A was subgrouped into A1/A2 at 3.5% divergence.

Table 2. Acriflavine resistance of *E. rhusiopathiae* field isolates and vaccine reference strains

Strain	MIC of Acriflavine (% w/v)	Acriflavine resistance ^{a)}
SY091027	0.02	R
NZ130701	0.005	S
HX130709	0.0025	S
XC130710	0.02	R
SH130723	0.02	R
YC130820	0.0025	S
YC130828	0.005	S
YC131115	0.0175	R
G ₄ T ₁₀ (vaccine)	0.02	R

a) Resistant (R) or sensitive (S) to 0.01% acriflavine.

four *spaA*-types. No nucleotide substitutions in the 432-bp hypervariable region on the *spaA* gene of all the archived attenuated strains were found comparing with the parental strain HX130709 (Table 4).

PFGE and data analysis: Eight distinct PFGE patterns with 22 to 30 DNA fragment bands were produced from the genomic DNA of the 8 isolate strains and 1 vaccine strain G₄T₁₀ with *Sma*I digestion (Fig. 2). Strains XC130710 and SH130723 shared the same PFGE pattern. Genetic relationships among the isolates were compared, and the dendrogram analysis was done (Fig. 1). Based on the dendrogram analysis, 3 PFGE groups (A-C) were present at 5% divergence. At 3.5% divergence, group A was subgrouped into A1/A2. Most of the isolates (6/9) were within group A including the vaccine strain G₄T₁₀. Resistance to acriflavine and *spaA*-types showed no specific patterns and were randomly distributed.

Table 3. Substitutions in nucleotide and amino acid in a 432-bp hypervariable region on the *spaA* gene of 8 *E. rhusiopathiae* field strains compared with the corresponding sequence of the vaccine strain G₄T₁₀

Substitution Pattern/strain	Substitutions (position [nucleotide], amino acid ^{a)})					No. of nucleotide substitutions	<i>spaA</i> type
	584 (A)	590 (T)	609 (T)	769 (A)	885 (A)		
	D>A	I>T	I>M	I>L	NS		
Pattern 1							
NZ130701	C					1	a
YC130820	C					1	a
SY091027	C					1	a
Pattern 2							
HX130709			G			1	b
SH130723			G			1	b
YC131115			G			1	b
Pattern 3							
YC130828	C				G	2	c
Pattern 4							
XC130710		C	G			2	d
Reference strain Fujisawa ^{b)}				C		1	

a) Original amino acid > substituted amino acid; NS=no amino acid mutation; G=glycine; D=aspartic acid; N=asparagine; A=alanine; I=isoleucine; T=threonine; M=methionine; L= leucine; E=glutamic acid. b) Japanese official challenge strain.

Table 4. Nucleotide substitutions in a 432-bp hypervariable region on the *spaA* gene of 11 *E. rhusiopathiae* strains during the attenuation compared with the corresponding sequence of the original strain HX130709

Concentration of acriflavine (% w/v)	Number of passage	Bacteria collected for <i>spaA</i> sequencing	No. of nucleotide substitutions	<i>spaA</i> type
0.0025	F1-F4			
0.00375	F5-F7	F5	0	b
0.005	F8-F10	F10	0	b
0.0125	F11-F12			
0.02	F13-F27	F15, F20, F25	0	b
0.0225	F28-F38	F30, F35	0	b
0.025	F39-F45	F40, F45	0	b
0.0275	F46-F48			
0.03	F49-F55	F50, F55	0	b
Reference strain HX130709	F0			b




Fig. 2. PFGE patterns produced from 8 erysipelas field isolates and 1 vaccine strain digested with *Sma* I. Lanes: 1, G₄T₁₀; 2, NZ130701; 3, HX130709; 4, XC130710; 5, SH130723; 6, YC130820; 7, YC130828; 8, SY091027; 9, YC131115; M, Lambda ladder PFG marker (N0340s, NEB).

Data analysis of the homogeneity of the PFGE patterns showed that these 9 strains shared over 92.1% identity with each other.

The PFGE patterns produced from the genomic DNA of the 12 archived strains during the attenuation with *Sma*I digestion are shown in Supplemental Fig. 1. The PFGE patterns of these 12 strains were very similar with each other. A few changes of patterns occurred between strains F10 and F15, but strains F15-F55 almost shared the same PFGE pattern. Based on the dendrogram analysis, 2 PFGE groups (A-B) were present at 5.8% divergence (Fig. 3). Most of the strains (9/12) belonged to group A in which these 9 strains shared over 99.5% identity with each other.

Pathogenicity towards mice: The results of the pathogenicity towards mice are shown in Figs. 3 and 4. Regardless of the acriflavine resistance, PFGE patterns or *spaA* types, all the 8 isolates and the early passages of the attenuated strains (F5, F10, F15, F20, F25, F30, F35, F40 and F45) showed high levels of virulence in mice. All mice died within 5 days after receiving subcutaneous injections of 10⁴ CFU of the strains, while all those injected with the attenuated strains (G₄T₁₀, F50 and F55) and PBS survived for the end of the experiment.

Antimicrobial susceptibility: Diameters of the bacteriostatic circles of the 8 isolates, vaccine strain G₄T₁₀ and the attenuated strain HX130709a (F55) against the 15 antimicrobial agents are shown in Table 5. All the strains were highly




Fig. 3. Genetic relationship among the 12 archived *E. rhusiopathiae* strains during the attenuation and their pathogenicity towards mice. The classification and divergence of the strains were calculated by the unweighted pair group method with averages from the PFGE results (Supplemental Fig. 1). At 5.8% divergence, 2 PFGE groups (A-B) were present. Most of the strains (9/12) were within group A in which these 9 strains shared over 99.5% identity with each other. Each mouse in different groups was injected with 0.1 ml/PBS and 10⁴ CFU strains F0-F55, respectively. Mice were observed daily to detect clinical signs of the disease for the subsequent 14 days. Only 3 groups survived for the end of the experiment after receiving subcutaneous injections of 10⁴ CFU of strains F50 and F55 and PBS, while other groups injected with 10⁴ CFU of strains F0-F45 died within 5 days.




Fig. 4. Pathogenicity of the 8 *E. rhusiopathiae* field strains towards mice. Each mouse of the untreated control group received a subcutaneous injection of 0.1 ml PBS in the right groin and was observed every 12 hr as others. Almost every mouse injected with 10^4 CFU *E. rhusiopathiae* field strains died within 72 hr, while all mice injected with 10^4 vaccine strain G_4T_{10} and PBS survived for the end of the experiment.

sensitive to PC-G, AMP, CEZ, CTX, EM, ROXM and AMO. Half of the isolates (HX130709, XC130710, SH 130723 and YC131115) were resistant to SM, TC, DOXY and LCM, and the other isolates (NZ130701, YC130820, YC130828 and SY091027) were moderately resistant to these antibiotics. KM and SXZ showed no activity against any of the strains.

Compared with strain HX130709, the attenuated strain HX130709a (F55) was much more sensitive to these antibiotics, except for KM, SXZ, ERFX and CIP.

DISCUSSION

Swine erysipelas used to be widely spread twenty years ago in China, which was later well controlled due to the wide use of antibiotics. In the present study, all the eight *E. rhusiopathiae* isolates were from cases of septicemia and were determined to be serotype 1a.

The acriflavine resistance has been used as one of the tools for discriminating the vaccine strain from field isolates because the live vaccine strain could grow in media containing at least 0.02% acriflavine, while the field strains are usually sensitive to acriflavine. Some acriflavine-resistant *E. rhusiopathiae* strains have been isolated from slaughter pigs affected by chronic arthritis [8, 9, 14]. It's worth mentioning that among the eight *E. rhusiopathiae* strains isolated from septicemia cases in this study, 3 (37.5%) virulent isolates (SY091027, XC130710 and SH130723) showed culture growth on the BHI-T 80 agar containing 0.02% acriflavine as the vaccine strain G_4T_{10} did.

Borrathybay *et al.* [6] proved that SpaA plays an important role in enhancing the virulence of *E. rhusiopathiae* strains. A method for discrimination between a Japanese vaccine strain and the field strains was developed based on the nucleotide sequencing of a 432-bp hypervariable region in the *spaA* gene [11]. In this study, *spaA* gene analysis showed that no mutations occurred among different passages of strain HX130709a comparing with the parental strain HX130709, which further confirmed that the virulence of serotype 1a *E. rhusiopathiae* strains isolated from acute swine erysipelas outbreaks in Eastern China is unrelated with some point mutations in the hypervariable region of the *spaA* gene.

Prevalence of Met-203 type *spaA* variant in *E. rhusiopathiae* isolates is increasing in Japan [20]. Interestingly,

Table 5. Antimicrobial susceptibility testing results of 8 *E. rhusiopathiae* field strains, the vaccine strain G_4T_{10} and the attenuated strain HX130709a

Antibiotic susceptibility discs ^{a)}	Diameter of bacteriostatic circle (mm) ^{b)}										No. of resistant strains (%)
	G_4T_{10}	NZ 130701	XC 130710	SH 130723	YC 130820	YC 130828	YC 131115	SY 091027	HX 130709	HX 130709a	
PC-G	40/S	42/S	42/S	40/S	38/S	39/S	42/S	38/S	40/S	54/S	
AMO	40/S	39/S	42/S	40/S	39/S	40/S	42/S	40/S	43/S	55/S	
AMP	36/S	38/S	36/S	34/S	38/S	36/S	40/S	34/S	36/S	46/S	
CEZ	32/S	35/S	35/S	34/S	34/S	32/S	36/S	33/S	34/S	41/S	
CTX	37/S	36/S	36/S	42/S	34/S	34/S	38/S	33/S	37/S	47/S	
SM	17/S	12/I	6.5/R	6.5/R	14/I	14/I	6.5/R	12/I	6.5/R	23/S	4 (40)
KM	6.5/R	6.5/R	6.5/R	6.5/R	6.5/R	6.5/R	6.5/R	6.5/R	6.5/R	6.5/R	10 (100)
TC	26/S	30/S	9/R	10/R	27/S	27/S	12/R	26/S	14/R	39/S	4 (40)
DOXY	25/I	30/S	11/R	14/R	25/I	26/I	18/R	27/I	15/R	36/S	4 (40)
EM	32/S	35/S	33/S	34/S	24/S	32/S	30/S	35/S	39/S	44/S	
ROXM	30/S	31/S	31/S	30/S	22/I	30/S	29/S	27/S	30/S	42/S	
LCM	36/S	33S	11.5/R	14/R	6.5/R	32/S	9/R	30/S	13/R	42/S	5 (50)
SXZ	6.5/R	6.5/R	10/R	8/R	6.5/R	6.5/R	6.5/R	6.5/R	6.5/R	10/R	10 (100)
ERFX	36/S	6.5/R	16/I	11/R	17/I	19/I	12/R	34/S	15/I	10/R	4 (40)
CIP	30/S	6.5/R	20/I	18/I	18.5/I	18.5/I	17/I	36/S	18/I	16/I	1 (10)

a) penicillin (PC-G), amoxicillin (AMO), ampicillin (AMP), cefazolin (CEZ), cefotaxime (CTX), streptomycin (SM), kanamycin (KM), tetracycline (TC), doxycycline (DOXY), erythromycin (EM), roxithromycin (ROXM), lincomycin (LCM), sulfisoxazole (SXZ), enrofloxacin (ERFX) and ciprofloxacin (CIP). b) The diameter of antibiotic susceptibility discs is 6.35 ± 0.50 mm. S=susceptible; I=intermediate; R=resistance.

four of the eight isolates in our study belonged to Met-203 type, and the other four field isolates belonged to Ala-195 type (Supplemental Table 1). A further study should be carried out to investigate the prevalence of Met-203 type *spaA* variant in *E. rhusiopathiae* isolates in China.

Based on the dendrogram analysis, the nine strains shared over 92.1% identity with each other, showing no correlations with *spaA*-type and resistance to acriflavine (Fig. 1).

Results of the drug susceptibility test showed that all the strains were highly sensitive to a variety of antibiotics, such as PC-G, AMP, CEZ, CTX, EM, ROXM and AMO, and also resistant to KM and SXZ, which well explained why swine erysipelas was easy to control with the use of antibiotics. However, nearly half of the isolates showed resistance to LCM, SM, TC, DOXY, SXZ and ERFX, because these antibiotics were widely added in the pig feeds in China [23].

With the emergence of new types of *E. rhusiopathiae* strains which are resistant to the widely used antibiotics, vaccines seem to be a better choice in controlling swine erysipelas. However, attenuated vaccine strains carry the risk of regaining their virulence thus, posing a hazard to susceptible swine, and the inactivated vaccines are rarely used because of the higher vaccination cost [22]. So, it is extremely urgent to develop more effective and safer subunit or gene engineering vaccines with virulence factor. However, the attenuation mechanism of *E. rhusiopathiae* strains remains unknown. Though *spaA* gene analysis showed that no mutations occurred during the attenuation, the mutations probably occurred in different important points of genome. So, all the archived strains (F5, F10, F15, F20, F25, F30, F35, F40, F45, F50 and F55) and the original strain HX130709 (F0) were analyzed using PFGE to detect whether any genome changes occurred during the attenuation. The PFGE patterns of the above 12 strains were very similar with each other (Supplemental Fig. 1). A few changes of the PFGE patterns occurred between strains F10 and F15, but strains F15-F55 shared over 99.5% identity with each other (Fig. 3). Surprisingly, though strains F15-F55 shared almost the same PFGE patterns, only strains F50 and F55 were avirulent (Fig. 3). This indicates the attenuation occurred between F46 and F50 and the mutations of *SmaI* Restriction Enzyme cutting site in the genome of the strains did not lead to any change of the virulence. It's possible that the mutations in the genome which directly lead to virulence loss cannot be detected by PFGE with *SmaI* digestion. In this case, comparing the entire genome of wild strain and the attenuated strain may be a good way to understand the attenuation mechanism. But, there is also another possibility that the strain virulence was decreased during the attenuation mainly by phenotype changes instead of genotype changes [10].

In this study, we conclude that the acute swine erysipelas outbreaks in Eastern China were caused by serotype 1a *E. rhusiopathiae* strains with different biochemical characteristics, and the virulence of serotype 1a *E. rhusiopathiae* strains is unrelated with some point mutations in hypervariable region of the *spaA* gene. Meanwhile, the attenuated strain HX130709a was obtained from a highly virulent clinical strain HX130709 after 55 passages on agar plates containing

acriflavine. Also, its virulence had been confirmed in mice, which lays the foundation for a further study of virulence factor of *E. rhusiopathiae* with proteomics and transcriptomic technologies.

ACKNOWLEDGMENTS. This study was supported by public welfare Grants from the Ministry of Agriculture, the People's Republic of China (201203039) and Priority Academic Program Development of Jiangsu Higher Education Institutions (PAPD). The authors thank Dr. Tanja Opriessnig (Veterinary Diagnostic Laboratory, College of Veterinary Medicine, Iowa State University, Ames, Iowa, U.S.A.) for offering to test serovars of the *E. rhusiopathiae* isolates.

REFERENCES

- Bender, J. S., Shen, H. G., Irwin, C. K., Schwartz, K. J. and Opriessnig, T. 2010. Characterization of Erysipelothrix species isolates from clinically affected pigs, environmental samples, and vaccine strains from six recent swine erysipelas outbreaks in the United States. *Clin. Vaccine Immunol.* **17**: 1605–1611. [[CrossRef](#)] [[Medline](#)]
- Bender, J. S., Irwin, C. K., Shen, H. G., Schwartz, K. J. and Opriessnig, T. 2011. *Erysipelothrix* spp. genotypes, serotypes, and surface protective antigen types associated with abattoir condemnations. *J. Vet. Diagn. Invest.* **23**: 139–142. [[CrossRef](#)] [[Medline](#)]
- Brooke, C. J. and Riley, T. V. 1999. *Erysipelothrix rhusiopathiae*: bacteriology, epidemiology and clinical manifestations of an occupational pathogen. *J. Med. Microbiol.* **48**: 789–799. [[CrossRef](#)] [[Medline](#)]
- Clinical and Laboratory Standards Institute (CLSI) 2009. Performance standards for antimicrobial disk susceptibility tests, approved standard – 10th ed., M02-A10, CLSI, Wayne.
- Eamens, G. J., Forbes, W. A. and Djordjevic, S. P. 2006. Characterisation of *Erysipelothrix rhusiopathiae* isolates from pigs associated with vaccine breakdowns. *Vet. Microbiol.* **115**: 329–338. [[CrossRef](#)] [[Medline](#)]
- Borrathybay, E., Gong, F. J., Zhang, L. and Nazierbieke, W. 2014. Role of surface protective antigen A in the pathogenesis of *Erysipelothrix rhusiopathiae* strain C43065. *J. Microbiol. Biotechnol.* DOI: 10.1407/jmb.1407-07058 [[Medline](#)]
- Imada, Y., Goji, N., Ishikawa, H., Kishima, M. and Sekizaki, T. 1999. Truncated surface protective antigen (SpaA) of *Erysipelothrix rhusiopathiae* serotype 1a elicits protection against challenge with serotypes 1a and 2b in pigs. *Infect. Immun.* **67**: 4376–4382. [[Medline](#)]
- Imada, Y., Takase, A., Kikuma, R., Iwamaru, Y., Akachi, S. and Hayakawa, Y. 2004. Serotyping of 800 strains of *Erysipelothrix* isolated from pigs affected with erysipelas and discrimination of attenuated live vaccine strain by genotyping. *J. Clin. Microbiol.* **42**: 2121–2126. [[CrossRef](#)] [[Medline](#)]
- Makino, S., Yamamoto, K., Murakami, S., Shirahata, T., Uemura, K., Sawada, T., Wakamoto, H. and Morita, H. 1998. Properties of repeat domain found in a novel protective antigen, SpaA, of *Erysipelothrix rhusiopathiae*. *Microb. Pathog.* **25**: 101–109. [[CrossRef](#)] [[Medline](#)]
- Muramatsu, M., Sawada, T. and Seto, K. 1975. Recovery of virulence of attenuated strain Koganei by passage in broth media containing Tween 80. *Annu. Rep. Natl. Vet. Assay Lab.* **12**: 3–8.
- Nagai, S., To, H. and Kanda, A. 2008. Differentiation of *Erysipelothrix rhusiopathiae* strains by nucleotide sequence analysis

- of a hypervariable region in the spaA gene: discrimination of a live vaccine strain from field isolates. *J. Vet. Diagn. Invest.* **20**: 336–342. [[CrossRef](#)] [[Medline](#)]
12. Okatani, A. T., Uto, T., Taniguchi, T., Horisaka, T., Horikita, T., Kaneko, K. and Hayashidani, H. 2001. Pulsed-field gel electrophoresis in differentiation of *erysipelothrix* species strains. *J. Clin. Microbiol.* **39**: 4032–4036. [[CrossRef](#)] [[Medline](#)]
 13. Opriessnig, T., Hoffman, L. J., Harris, D. L., Gaul, S. B. and Halbur, P. G. 2004. *Erysipelothrix rhusiopathiae*: genetic characterization of midwest US isolates and live commercial vaccines using pulsed-field gel electrophoresis. *J. Vet. Diagn. Invest.* **16**: 101–107. [[CrossRef](#)] [[Medline](#)]
 14. Ozawa, M., Yamamoto, K., Kojima, A., Takagi, M. and Takahashi, T. 2009. Etiological and biological characteristics of *Erysipelothrix rhusiopathiae* isolated between 1994 and 2001 from pigs with swine erysipelas in Japan. *J. Vet. Med. Sci.* **71**: 697–702. [[CrossRef](#)] [[Medline](#)]
 15. Seto, K., Nishimura, Y., Fujiki, M., Azechi, H. and Suzuki, K. 1971. Studies on acriflavine-fast attenuated *Erysipelothrix insidiosa*. Comparison on pathogenicity and immunogenicity between mice and pigs. *Jpn. J. Vet. Sci.* **33**: 161–171. [[CrossRef](#)]
 16. Shimoji, Y., Mori, Y. and Fischetti, V. A. 1999. Immunological characterization of a protective antigen of *Erysipelothrix rhusiopathiae*: identification of the region responsible for protective immunity. *Infect. Immun.* **67**: 1646–1651. [[Medline](#)]
 17. Takahashi, T., Nagamine, N., Kijima, M., Suzuki, S., Takagi, M., Tamura, Y., Nakamura, M., Muramatsu, M. and Sawada, T. 1996. Serovars of *Erysipelothrix* strains isolated from pigs affected with erysipelas in Japan. *J. Vet. Med. Sci.* **58**: 587–589. [[CrossRef](#)] [[Medline](#)]
 18. To, H. and Nagai, S. 2007. Genetic and antigenic diversity of the surface protective antigen proteins of *Erysipelothrix rhusiopathiae*. *Clin. Vaccine Immunol.* **14**: 813–820. [[CrossRef](#)] [[Medline](#)]
 19. To, H., Sato, H., Tazumi, A., Tsutsumi, N., Nagai, S., Iwata, A. and Nagano, T. 2012. Characterization of *Erysipelothrix rhusiopathiae* strains isolated from recent swine erysipelas outbreaks in Japan. *J. Vet. Med. Sci.* **74**: 949–953. [[CrossRef](#)] [[Medline](#)]
 20. Uchiyama, M., Yamamoto, K., Ochiai, M., Yamamoto, T., Hirano, F., Imamura, S., Nagai, H., Ohishi, K., Horiuchi, N. and Kijima, M. 2014. Prevalence of Met-203 type spaA variant in *Erysipelothrix rhusiopathiae* isolates and the efficacy of swine erysipelas vaccines in Japan. *Biologicals* **42**: 109–113. [[CrossRef](#)] [[Medline](#)]
 21. Wood, R. L. and Harrington, R. Jr. 1978. Serotypes of *Erysipelothrix rhusiopathiae* isolated from swine and from soil and manure of swine pens in the United States. *Am. J. Vet. Res.* **39**: 1833–1840. [[Medline](#)]
 22. Wood, R. L. 1999. Erysipelas. pp. 419–430. In: *Diseases of Swine*, 8th ed. (Straw, B. E, D’Allaire, S., Mengeling, M. L. and Taylor, D. J. eds.), Iowa State University Press, Ames.
 23. Yunpeng, W. and Yue, M. 2008. Potential public hazard of using antibiotics in livestock industry. *Chin. J. Antibiot.* **33**: 519–523.